Skip to main content

Stueland Katherine's Form 4 filing

GeneDx Holdings Corp. (WGS) · filed Mar 17, 2025

Accession no.
0001415889-25-008282
Filed
Mar 17, 2025
Trade date
Mar 26, 2024-Mar 17, 2025
Filing delay
356 daysLate
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions and 3 derivative transactions. Open-market sales total $1.12M. It was filed 356 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Stueland KatherineCIK 0001689575Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 13, 2025Class A Common StockSSaleDisposed−1,078$89.44F2−$96,416.326,674Direct
Mar 16, 2025Class A Common StockMOption exerciseAcquired+18,750$0.00F3$025,424Direct
Mar 17, 2025Class A Common StockSSaleDisposed−10,559$96.71F4−$1,021,160.8914,865Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 26, 2024Class A Common StockAGrant or awardAcquired+320,000$0.00$0320,000Direct
Mar 15, 2025Class A Common StockAGrant or awardAcquired+47,684$0.00$047,684Direct
Mar 16, 2025Class A Common StockMOption exerciseDisposed−18,750$0.00$0150,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.695 to $89.45 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F3

Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

Referenced by the price of 1 transaction in Table I.

F4

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.30 to $96.71 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)